SNORD17 and hepatocellular carcinoma: SNORD17 facilitates hepatocellular carcinoma (HCC) progression by anchoring nucleophosmin 1 (NPM1) and MYB binding protein 1a (MYBBP1A) in the nucleolus, leading to p53 inhibition [7].